About Cyclopharma
Cyclopharma is a company based in Gerzat (France) founded in 2000 was acquired by Curium in April 2018. Cyclopharma has raised $2.95 million across 1 funding round from investors including Curium Pharma and IXO. Cyclopharma operates in a competitive market with competitors including ImaginAb, AC Immune, APRINOIA, Innovate Biopharma and Progenics, among others.
- Headquarter Gerzat, France
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.95 M (USD)
in 1 rounds
-
Latest Funding Round
$2.95 M (USD), Private Equity Round
May 04, 2017
-
Investors
Curium Pharma
& 1 more
-
Employee Count
Not available
-
Acquired by
Curium
(Apr 11, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Cyclopharma
Cyclopharma has successfully raised a total of $2.95M through 1 strategic funding round. The most recent funding activity was a Private Equity Round of $2.95 million completed in May 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cyclopharma
Cyclopharma has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Curium Pharma and IXO.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments in France are managed by IXO.
|
Locked | Locked | Locked | |
|
Curium Pharma is recognized as a leader in radiopharmaceuticals.
|
Locked | Locked | Locked |
Investor details for Cyclopharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cyclopharma
Investment portfolio details for Cyclopharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cyclopharma
Detailed financials for Cyclopharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cyclopharma Comparisons
Peer comparison for Cyclopharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cyclopharma
Cyclopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ImaginAb, AC Immune, APRINOIA, Innovate Biopharma and Progenics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
|
|
| Locked | Locked | Locked |
Antibodies, small molecules, and vaccines are developed for neurodegenerative diseases.
|
|
| Locked | Locked | Locked |
Diagnostics and therapeutics for neurodegenerative disorders are developed.
|
|
| Locked | Locked | Locked |
Small molecule drugs and imaging agent for GI disorders
|
|
| Locked | Locked | Locked |
Imaging compounds & targeted radiotherapies to detect and treat prostate cancer.
|
|
| Locked | Locked | Locked |
Cancer diagnosis devices targeting VPAC1 receptors are developed.
|
Detailed competitors of Cyclopharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cyclopharma
Complete news archive for Cyclopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cyclopharma
Cyclopharma was founded in 2000 and raised its 1st funding round 17 years after it was founded.
Cyclopharma is headquartered in Gerzat, France. It is registered at Gerzat, Puy-de-dome, France.
Bernard Salin is the current CEO of Cyclopharma.
Cyclopharma is a funded company, having raised a total of $2.95M across 1 funding round to date.
Cyclopharma was established in 2000 in Gerzat, France, within the radiopharmaceutical sector. Radiopharmaceuticals for molecular imaging applications are developed and produced by the company. Research and development efforts are concentrated on oncology, cardiology, and neurology. The oncology program SEI810 is advanced to clinical trials, while additional programs remain in early proof-of-concept stages. Operations are centered in Europe, supporting diagnostic and therapeutic advancements.
Cyclopharma has 2 investors. Key investors include Curium Pharma, and IXO.